Abstract 307P
Background
Few studies, conducted in the late 1980s, failed to demonstrate increased overall survival (OS) for early breast cancer patients receiving intensive follow up (IFU). We evaluated, in a modern cohort of patients, survival outcomes of metastatic breast cancer patients (mBC pts) according to the type of diagnosis of metastatic disease.
Methods
The GIM14/BIO-META is an ongoing italian retrospective/prospective observational multicenter study enrolling consecutive mBC pts. For the present analysis, mBC pts relapsed after treatment for primary tumor were divided in two groups according to the type of diagnosis of metastatic disease: standard follow up (SFU; suspicious signs or symptoms of metastatic disease at routine follow up visits) or IFU (increased tumor markers or metastatic lesion detected with routine radiological exams). Primary objective was to compare OS between SFU and IFU groups.
Results
From January 2000 to December 2019, 2752 mBC pts were enrolled of whom 1433 were included in the present analysis: 597 in the SFU group and 836 in the IFU group. Patients in the IFU group had a shorter median disease-free interval (60.6 and 52.9 months for SFU and IFU respectively, p=0.01). No differences in OS were observed with a median OS of 62.53 (95%CI 54.44-70.89) and 59.38 (95%CI 53.36-63.88) months for SFU and IFU groups respectively (HR 1.04, 95%CI 0.89-1.21, p=0.64). In the subgroup analysis, no differences in OS were observed according to nodal involvement of primary tumor and among HER2-positive and luminal-like breast cancer patients. A worse outcome was demonstrated for triple-negative breast cancer patients diagnosed through IFU (HR 1.98, 95%CI 1.30-3.04). Among the 157 HER2-positive mBC pts diagnosed after 2015, no differences in OS were demonstrated for patients diagnosed through SFU or IFU (HR 0.86 95%CI 0.44-1.67).
Conclusions
IFU seem to anticipate diagnosis of metastatic disease without increasing survival. Further randomized trials are needed to evaluate the role of different IFU strategies considering the current advances in imaging and anticancer treatments available nowadays.
Clinical trial identification
NCT02284581.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
O. Garrone: Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Other: Eisai; Financial Interests, Personal, Other: Novartis; Financial Interests, Personal, Other: Pfizer; Financial Interests, Personal, Other: Lilly. C. Bighin: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Invited Speaker: Pfizer. L. Del Mastro: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal and Institutional, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Other: Celgene; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Seagen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Eisai. All other authors have declared no conflicts of interest.